TP53 and neoplasm: This indicated that, in the acquired drug-resistant HCT116 nude mouse tumor model, p53 activity was not effectively activated during cGAMP monotherapy, and its ability to reverse drug resistance was limited, which was consistent with the results of tumor suppression in vivo (Figure 3D).